Ainos, Inc. (AIMD)
$
0.7
-0.05 (-7.14%)
Key metrics
Financial statements
Free cash flow per share
-0.3523
Market cap
15.6 Million
Price to sales ratio
146.6784
Debt to equity
0.9145
Current ratio
2.0027
Income quality
0.3733
Average inventory
142.8 Thousand
ROE
-0.8807
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Ainos, Inc. is a healthcare company that specializes in the development of medical technologies aimed at point-of-care testing and innovative treatments for various disease indications. The company has made significant strides in its financial performance, as evidenced by its operating income ratio of -667.72 indicating the company's operational profitability margin. Additionally, the gross profit ratio stands at -1.54 reflecting the efficiency of the company's production and sales operations. Ainos achieved a revenue of $20,729.00 showcasing its focus on niche markets. However, the company also incurred an interest expense of $616,467.00 highlighting its obligations related to debt servicing. The weighted average number of shares outstanding is 9,503,618.00 which underscores the company's shareholder base and their stake in the firm. Ainos offers a range of products, including a COVID-19 antigen rapid test kit, a cloud-based test management platform, and a low-dose oral interferon alpha formulation known as Very Low-Dose Oral Interferon Alpha, among other technologies. Formerly known as Amarillo Biosciences, Inc., the company rebranded to Ainos, Inc. in May 2021 and has its headquarters in San Diego, California. The company's stock presents an attractive option for budget-conscious investors, as it is affordable at $0.70. However, it's important to note that the stock has a low average trading volume of 262,982.00 indicating lower market activity, which may affect liquidity. With a market capitalization of $14,562,434.00 Ainos is classified as a small-cap player within the healthcare market. It operates within the Biotechnology industry and plays a crucial role in enhancing the overall market landscape. Furthermore, Ainos belongs to the Healthcare sector, where it continues to drive innovation and growth through its advanced medical technologies. The company's strategic focus on point-of-care testing and treatment positions it effectively in the evolving healthcare landscape, allowing it to contribute meaningfully to patient care and medical advancements.
Is Ainos, Inc. (AIMD) a good investment?
Investing in Ainos, Inc. (AIMD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Ainos, Inc. (AIMD)'s stock forecast?
Analysts predict Ainos, Inc. stock to fluctuate between $0.40 (low) and $1.17 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Ainos, Inc.'s market capitalization?
As of 2025-05-29, Ainos, Inc.'s market cap is $14,562,434, based on 20,773,800 outstanding shares.
How does Ainos, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Ainos, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Ainos, Inc. (AIMD) stock?
To buy Ainos, Inc. (AIMD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AIMD. Place an order (Market, Limit, etc.).
What is the best time to invest in Ainos, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Ainos, Inc. stock ever split?
Ainos, Inc.'s last stock split was 1:5 on 2023-12-14.
How did Ainos, Inc. perform in the last earnings report?
Revenue: $20,729 | EPS: -$1.56 | Growth: -53.57%.
Where can I find Ainos, Inc.'s investor relations reports?
Visit https://ainos.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Ainos, Inc.?
You can explore historical data from here
What is the all-time high and low for Ainos, Inc. stock?
All-time high: $90 (2022-08-04) | All-time low: $0.40 (2024-11-15).
What are the key trends affecting Ainos, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
a day ago
Accelerating Toward Commercial Rollout as AI Nose Solves Critical Gaps in Elder Care SAN DIEGO, CA / ACCESS Newswire / May 29, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, announced today that its proprietary AI Nose platform achieved approximately 85% accuracy in detecting excretion odors data, an improvement from 80% previously, based on collected from 254 participant instances in Japan and Taiwan, resulting in 2119 valid entries for subsequent statistical evaluation. The milestone validates AI Nose as a deploy able solution for non-contact hygiene monitoring in long-term care (LTC) and positions Ainos to lead the emerging SmellTech category.
accessnewswire.com
8 days ago
Robotic Smell Intelligence Goes Live at Asia's Premier AI Tech Stage SAN DIEGO, CA / ACCESS Newswire / May 22, 2025 / Ainos, Inc. (NASDAQ:AIMD)(Nasdaq:AIMDW) ("Ainos"), a pioneer in AI-driven scent digitization, announced the official debut of its proprietary AI Nose platform at COMPUTEX 2025, alongside ugo, Inc, Japan's top service robotics company. This milestone marks the first public demonstration of real-time robotic olfaction-a new sensory category poised to transform smart robotics, environmental AI, and safety infrastructure.
accessnewswire.com
11 days ago
Early results show steroid-free remission, opening pathway into $13B global pet dental health market VELDONA delivers consistent anti-inflammatory effects, strengthening Ainos' positioning in companion animal immunotherapy SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 19, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a pioneer of low-dose oral interferon therapeutics, today announced compelling interim results from its ongoing veterinary clinical trial using low-dose interferon VELDONA for treating Feline Chronic Gingivostomatitis ("FCGS"), a chronic inflammatory conditions in cats. The interim results demonstrate meaningful improvements in inflammation and a consistent reduction in steroid dependency, indicating strong commercial and scientific potential for a novel class of immunotherapy in companion animals.
accessnewswire.com
16 days ago
412% revenue growth reflects AI Nose sales in elderly care Expanding AI-driven scent tech beyond healthcare into robotics and industrial applications SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 14, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report highlighting the Company's significant progress in commercializing its AI-driven scent digitization platform, AI Nose, and expanding into multiple market verticals. Notably, Ainos has achieved a key milestone of achieving over 80% accuracy in its senior care project.
accessnewswire.com
18 days ago
Q1 revenues increased 412% year over year, driven by AI Nose products Delivers strong turnaround from gross loss to gross profit in Q1 AI Nose gains traction beyond healthcare with strategic partnerships in robotics and semiconductor sectors VELDONA® program advances with TFDA and IRB Approvals for two clinical trials in Taiwan SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 12, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company") today announced its financial results for the first quarter ended March 31, 2025. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "Q1 2025 represents a significant step forward in advancing our long-term strategy to build a differentiated healthcare and technology company powered by scent digitization, AI-enhanced diagnostics and innovative therapeutics.
accessnewswire.com
a month ago
Robotic smelltech by AI Nose moves from concept to integration in weeks Partnership fast-tracks robotic smell integration as global service robotics market nears $40.6B, Japan $1.2B SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 23, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report highlighting the Company's successful installation of its AI Nose technology onto a humanoid robot developed by ugo, Inc., Japan's leading service robot company. The milestone, achieved just weeks after announcing the partnership, demonstrates fast execution and marks a global first in robotic smell integration.
accessnewswire.com
a month ago
Milestone Ignites a New Era of Smell-Enabled Robotics Installs AI Nose in ugo Robot; Real-World Pilots to Begin in Weeks SAN DIEGO, CA / ACCESS Newswire / April 21, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, has successfully installed its proprietary AI Nose olfaction module on a humanoid robot developed by ugo, Inc. ("ugo"), Japan's top service robotics company. Completed on April 9, 2025, the installation marks the world's first robot with a functional sense of smell, a breakthrough that redefines the frontier of robotics, AI, and human-machine interaction.
accessnewswire.com
2 months ago
Dual Trials Accelerate VELDONA® Toward Rare Disease Market Entry Bridging Strategy Aims to Fast-Track U.S. Regulatory Approvals SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 14, 2025 / Ainos, Inc. (Nasdaq:AIMD, AIMDW) ("Ainos" or the "Company"), pioneer of low-dose oral interferon therapeutics, today announced significant progress in advancing its oral interferon drug platform, VELDONA® in the rare disease space. The Taiwan Food and Drug Administration (TFDA) has approved the Company's clinical trial for human immunodeficiency virus (HIV)-related oral warts, while Institutional Review Board (IRB) clearance has been granted for its upcoming Sjögren's Syndrome (pSS) study.
accessnewswire.com
2 months ago
Strategic partnerships and industry-leading accuracy position Ainos as a game-changer in digitized scent technology SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 11, 2025 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report spotlighting the Company's expansion of its AI Nose technology into the robotics and semiconductor sectors. The report features insights from a management fireside chat on April 8, 2025.
accessnewswire.com
2 months ago
SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 24, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that it will participate in a fireside chat with Do Kim, senior research analyst of Water Tower Research ("WTR") and John Roy, managing director of WTR on Tuesday, April 8, 2025, at 10:00 a.m. ET. Ainos will provide insights into AI Nose applications, including its use in smart manufacturing and robots, as well as the impact of AI-driven digitized smell on industries beyond healthcare.
See all news
